A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors
A phase 1/2 trial of Selpercatinib in thyroid cancer and sarcomas, run by Eli Lilly and Company, active and no longer recruiting.
Overview
A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors is a phase 1/2 interventional study registered as NCT03899792 by Eli Lilly and Company, with 36 participants enrolled, started 2019-06-13 and due to reach its primary completion in 2024-11-08. Interventions recorded: Selpercatinib. Conditions listed: Medullary Thyroid Cancer, Infantile Myofibromatosis, Infantile Fibrosarcoma, Papillary Thyroid Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Study of Selpercatinib (LY3527723) in Participants With Advanced Solid Tumors Including RET Fusion-positive Solid Tumors, Medullary Thyroid Cancer a
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
- TrialA Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRET
Shares Selpercatinib, Eli Lilly (incl. Loxo), Thyroid cancer.
- TrialA Study of Selpercatinib After Surgery or Radiation in Participants With Non-Small Cell Lung Cancer (NSCLC)
Shares Selpercatinib, Eli Lilly (incl. Loxo).
- TreatmentOlaratumab
Shares Eli Lilly (incl. Loxo), Sarcomas (soft tissue, bone, GIST).
- PersonLori J. Wirth
Shares Selpercatinib, Thyroid cancer.
- PersonAlexander Drilon
Shares Selpercatinib, Thyroid cancer.
- TrialLIBRETTO-531
Shares Selpercatinib, Thyroid cancer.
- IdeaRandomise inside the registry that already follows every patient